Eledon Pharmaceuticals (ELDN) Expected to Announce Earnings on Wednesday

Eledon Pharmaceuticals (NASDAQ:ELDN) is anticipated to post its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Eledon Pharmaceuticals to post earnings of ($0.22) per share for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.

Eledon Pharmaceuticals (NASDAQ:ELDN) last announced its quarterly earnings results on Thursday, March 19th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.10.

Eledon Pharmaceuticals Price Performance

Shares of NASDAQ:ELDN opened at $3.78 on Wednesday. Eledon Pharmaceuticals has a 12 month low of $1.35 and a 12 month high of $4.60. The business’s 50 day simple moving average is $3.06 and its 200-day simple moving average is $2.48. The firm has a market capitalization of $286.72 million, a price-to-earnings ratio of -7.27 and a beta of 0.94.

Institutional Investors Weigh In On Eledon Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets lifted its stake in Eledon Pharmaceuticals by 143.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,154 shares of the company’s stock valued at $31,000 after buying an additional 7,166 shares in the last quarter. Millennium Management LLC purchased a new stake in Eledon Pharmaceuticals in the 4th quarter valued at approximately $36,000. Virtu Financial LLC purchased a new stake in Eledon Pharmaceuticals in the 4th quarter valued at approximately $39,000. Cetera Investment Advisers lifted its stake in Eledon Pharmaceuticals by 72.9% in the 4th quarter. Cetera Investment Advisers now owns 26,584 shares of the company’s stock valued at $40,000 after buying an additional 11,207 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in Eledon Pharmaceuticals in the 4th quarter valued at approximately $45,000. Hedge funds and other institutional investors own 56.77% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eledon Pharmaceuticals in a research note on Friday, March 27th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $9.67.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.

Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.